Effect of (S)-4-(1-(5-chloro-2-(4-fluorophenyoxy)benzamido)ethyl) benzoic acid (CJ-42794), a selective antagonist of prostaglandin E receptor subtype 4, on ulcerogenic and healing responses in rat gastrointestinal mucosa

Journal of Pharmacology and Experimental Therapeutics

Volumn 322, Issue 3, 2007, Pages 903-912

  Takeuchi, Koji ^a   Tanaka, Akiko ^a   Kato, Shinichi ^a   Aihara, Eitaro ^a   Amagase, Kikuko ^a  

^a KYOTO PHARMACEUTICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

4 [1 [5 CHLORO 2 (4 FLUOROPHENYOXY)BENZAMIDO]ETHYL]BENZOIC ACID; 5 (4 CHLOROPHENYL) 1 (4 METHOXYPHENYL) 3 TRIFLUOROMETHYL 1H PYRAZOLE; ACETYLSALICYLIC ACID; CJ 42794; CYCLOOXYGENASE 2 INHIBITOR; INDOMETACIN; PROSTAGLANDIN E RECEPTOR; PROSTAGLANDIN E RECEPTOR 4; PROSTAGLANDIN RECEPTOR BLOCKING AGENT; PROSTAGLANDIN SYNTHASE INHIBITOR; RECEPTOR SUBTYPE; ROFECOXIB; UNCLASSIFIED DRUG; VASCULOTROPIN;

ADJUVANT ARTHRITIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHRONIC DISEASE; COLD STRESS; COMPARATIVE STUDY; CONTROLLED STUDY; DIGESTIVE SYSTEM ULCER; DISEASE EXACERBATION; DOSE RESPONSE; DRUG EFFECT; EXPERIMENTAL RAT; GASTROINTESTINAL MUCOSA; IMMOBILIZATION STRESS; LOW DRUG DOSE; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; RECEPTOR DOWN REGULATION; ULCER HEALING; ULCEROGENESIS;

ANIMALS; BENZAMIDES; BENZOIC ACIDS; GASTRIC MUCOSA; INDOMETHACIN; INTESTINAL MUCOSA; LACTONES; PEPTIC ULCER; RATS; RECEPTORS, PROSTAGLANDIN E; STOMACH ULCER; SULFONES; WOUND HEALING;

EID: 34548093500     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.107.122978     Document Type: Article

References (42)

1. Aihara E, Nomura Y, Sasaki Y, Ise F, Kita K, and Takeuchi K (2007) Involvement of prostaglandin E receptor EP3 subtype in duodenal bicarbonate secretion in rats. Life Sci 80:2446-2453.
2. 2/EP3 signaling regulates tumor-associated angiogenesis and tumor growth. J Exp Med 197:221-232.
3. Aoi M, Aihara E, Nakashima M, and Takeuchi K (2004) Participation of prostaglandin E receptor subtype in duodenal bicarbonate secretion in rats. Am J Physiol Gastrointest Liver Physiol 287:G96-G103.
4. Arai I, Hamasaka Y, Futaki N, Takahashi S, Yoshikawa K, Higuchi S, and Otomo S (1993) Effect of NS-398, a new nonsteroidal anti-inflammatory agent, on gastric ulceration and acid secretion in rats. Res Commun Chem Pathol Pharmacol 81:259-270.
5. 2 in rat stomachs. Aliment Pharmacol Ther 14 (Suppl 1):18-25.
6. Chan CC, Boyce S, Bridear C, Ford-Hutchinson AW, Gordon R, Guay D, Li CS, Mancini J, Panneton M, Prasit P, et al. (1995) Pharmacology of a selective cyclooxygenase-2 inhibitor L-745,337: a novel nonsteroidal anti-inflammatory agent with an ulcerogenic sparing effect in rat and non-human primate stomach. J Pharmacol Exp Ther 274:1531-1537.
7. Fiorucci S, de Lima OM Jr, Mencarelli A, Palazzetti B, Distrutti E, McKnight W, Dicay M, Ma L, Romano M, Morelli A, et al. (2002) Cyclooxygenase-2-derived lipoxin A4 increases gastric resistance to aspirin-induced damage. Gastroenterology 123:1598-1606.
8. Futaki N, Takahashi S, Yokoyama M, Arai I, Higuchi S, and Otomo S (1994) NS-938, a new antiinflammatory agent, selectively inhibits prostaglandin G/H synthase/cyclooxygenase (COX-2) activity in vitro. Prostaglandins 47:55-59.
9. Hatazawa R, Ohno R, Tanigami M, Tanaka A, and Takeuchi K (2006) Roles of endogenous prostaglandins and cyclooxygenase isozyme in healing of indomethacin-induced small intestinal lesions in rats. J Pharmacol Exp Ther 318:691-699.
10. Kabashima K, Saji T, Murata T, Nagamachi M, Matsuoka T, Segi E, Tsuboi K, Sugimoto Y, Kobayashi T, Miyachi Y, et al. (2002) The prostaglandin receptor EP4 suppresses colitis, mucosal damage and CD4 cell activation in the gut. J Clin Invest 109:883-893.
11. Kato K, Fukushima K, Amagase K, and Takeuchi K (2006) Aggravation of indomethacin-induced intestinal ulceration in rats with adjuvant-induced chronic arthritis: involvement of increased expression of Toll-like receptor (TLR)-4 (Abstract). Gastroenterology 130: A488.
12. Kato S, Ogawa Y, Kanatsu K, Watanabe T, Arakawa T, and Takeuchi K (2002) Ulcerogenic influence of selective cyclooxygenase (COX)-2 inhibitors in the rat stomach with adjuvant-induced arthritis. J Pharmacol Exp Ther 303:503-509.
13. Kato S, Tanaka A, Konaka A, Kunikata T, and Takeuchi K (1999) Changes in gastric mucosal ulcerogenic responses in rats with adjuvant arthritis: role of nitric oxide. Aliment Pharmacol Ther 13:833-840.
14. Konturek PK, Brzozowski T, Konturek SJ, and Dembinski A (1990) Role of epidermal growth factor, prostaglandin, and sulfhydryls in stress-induced gastric lesions. Gastroenterology 99:1607-1615.
15. 2 inhibits indomethacin-induced small intestinal lesions through EP3 and EP4 receptors. Dig Dis Sci 47:894-904.
16. Laemmli UK (1970) Cleavage of structural proteins during assembly of the head of bacteriophage T4. Nature 227:680-685.
17. Lanza FL (1984) Endoscopic studies of gastric and duodenal injury after the use of ibuprofen, aspirin, and other nonsteroidal antiinflammatory agents. Am J Med 77:19-24.
18. 2 receptor EP4 contributes to inflammatory pain hypersensitivity. J Pharmacol Exp Ther 319:1096-1103.
19. Miura S, Tatsuguchi A, Wada K, Takeyama H, Shinji Y, Hiratsuka T, Futagami S, Miyake K, Gudis K, Mizokami Y, et al. (2004) Cyclooxygenase-2- regulated vascular endothelial growth factor release in gastric fibroblasts. Am J Physiol Gastrointest Liver Physiol 287:G444-G451.
20. Mukherjee D, Nissen SE, and Topol EJ (2001) Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA 286:954-959.
21. Narumiya S and FitzGerald GA (2001) Genetic and pharmacological analysis of prostanoid receptor function. J Clin Invest 108:25-30.
22. Ohno R, Yokota A, Tanaka A, and Takeuchi K (2004) Induction of small intestinal damage in rats following combined treatment with cyclooxygenase-2 and nitric oxide synthase inhibitors. J Pharmacol Exp Ther 310:821-827.
23. Souza MH, de Lima OM Jr., Zamuner SR, Fiorucci S, and Wallace JL (2003) Gastritis increases resistance to aspirin-induced mucosal injury via COX-2-mediated lipoxin synthesis. Am J Physiol Gastrointest Liver Physiol 285:G54-G61.
24. Szabo S, Folkman J, Vattay P, Morales RE, Pinkus GS, and Kato K (1994) Accelerated healing of duodenal ulcers by oral administration of a mutein of basic fibroblast growth factor in rats. Gastroenterology 106:1106-1111.
25. Suzuki K, Araki H, Mizoguchi H, and Takeuchi K (2001) E type prostaglandin inhibits indomethacin-induced gastric lesions in rats through EP1 receptors: importance of antigastric motility action. Digestion 63:92-101.
26. Szabo S, Vincze A, Sandor ZS, and Gombos Z (1998) Vascular approach to gastroduodenal ulceration: new studies with endothelins and VEGF. Dig Dis Sci 43:40S-45S.
27. 2-stimulated mucus secretion by rabbit gastric epithelial cells. Biochem Pharmacol 58:1997-2002.
28. Takeuchi K, Araki H, Komoike Y, Umeda M, and Suzuki K (2001) Adaptive gastric cytoprotection is mediated by prostaglandin EP1 receptors: a study using rats and knockout mice. J Pharmacol Exp Ther 297:1160-1165.
29. Takeuchi K, Furukawa O, Tanaka H, and Okabe S (1986) A new model of duodenal ulcers induced in rats by indomethacin plus histamine. Gastroenterology 90:636-645.
30. Takeuchi K, Miyazawa T, Tanaka A, Kato S, and Kunikata T (2002) Pathogenic importance of intestinal hypermotility in NSAID-induced small intestinal damage in rats. Digestion 66:30-41.
31. Takeuchi K, Ukawa H, Kato S, Furukawa O, Araki H, Sugimoto Y, Ichikawa A, Ushikubi F, and Narumiya S (1999) Impaired duodenal bicarbonate secretion and mucosal integrity in mice lacking prostaglandin E receptor subtype EP3. Gastroenterology 117:1128-1135.
32. Tanaka A, Araki H, Hase S, Komoike Y, and Takeuchi K (2001) Inhibition of both COX-1 and COX-2 is required for development of gastric damage in response to nonsteroidal antiinflammatory drugs. J Physiol Paris 95:21-27.
33. Tanaka A, Hase S, Miyazawa T, and Takeuchi K (2002) Up-regulation of COX-2 by inhibition of COX-1: a key to NSAID-induced intestinal damage. J Pharmacol Exp Ther 300:754-761.
34. 2. Dig Dis Sci 52:478-487.
35. Tarnawski AS (2005) Cellular and molecular mechanisms of gastrointestinal ulcer healing. Dig Dis Sci 50:S24-S33.
36. Ukawa H, Yamakuni H, Kato S, and Takeuchi K (1998) Effects of cyclooxygenase-2 selective and nitric oxide-releasing nonsteroidal anti-inflammatory drugs on gastric ulcerogenic and healing responses in experimental animals. Dig Dis Sci 43:2003-2011.
37. Wallace JL, McKnight W, Reuter BK, and Vergnolle N (2000) NSAID-induced gastric damage in rats: Requirement for inhibition of both cyclooxygenase 1 and 2. Gastroeneterology 119:706-714.
38. Wang JY, Yamasaki S, Takeuchi K, and Okabe S (1989) Delayed healing of acetic acid-induced gastric ulcers in rats by indomethacin. Gastroenterology 96:393-402.
39. Woodhams PL, Macdonald RE, Collins SD, Chessell IP, and Day NC (2007) Localisationand modulation of prostanoid receptors EP1 and EP4 in the rat chronic constriction injury model of neuropathic pain. Eur J Pain 11:605-613.
40. 2 on a rat model of esophagitis mediated by EP1 receptors: relation to pepsin secretion. Digestion 72:109-118.
41. Yue L, Shen Y-X, Feng L-J, Chen F-H, Wei H, Liu L-H, Wu Q, and Wang H (2007) Blockage of the formation of new blood vessels by recombinant human endostatin contributes to the regression of rat adjuvant arthritis. Eur J Pharmacol 567:166-170.
42. Zeilhofer HU and Brune K (2006) Analgesic strategies beyond the inhibition of cyclooxygenases. Trends Pharmacol Sci 27:467-474.